EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment

Shuxiao Guan, Cankun Wang, Joseph M Amann, Ju Hwan Cho, Qin Ma, David P Carbone

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04330-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Shuxiao Guan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Receptor, Adenosine A2B, Programmed Cell Death 1 Receptor, Adenosine A2 Receptor Antagonists. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). However, their low response rates and poor 5-year survivals indicate a need for improvement. One key factor in this resistance may be molecules that mediate immunosuppression within the tumor microenvironment (TME), such as adenosine. Combining therapies that mitigate the effects of adenosine with ICIs could potentially overcome these limitations. METHODS: We utilized the Lewis lung carcinoma (LLC) and CMT167 murine lung carcinoma models to investigate the combined use of the A2B receptor antagonist PBF1129 and anti-PD-1 ICI. The mechanisms underlying the efficacy of this combination therapy were explored using single-cell RNA sequencing (scRNA-seq). RESULTS: In both models, combination therapy improved tumor control. Our scRNA-seq analysis characterized alterations in malignant cells, macrophages, cancer-associated fibroblasts (CAFs), T cells, and endothelial cells in the tumor after treatment. Malignant cells treated with combination therapy exhibited reduced inflammatory, epithelial-to-mesenchymal transition (EMT) and angiogenic signatures. Malignant cells and M2-like macrophages showed high expression of TGFβ pathway genes, which were significantly reduced in the combination therapy group. We also observed decreased interactions between M2-like macrophages and CAFs as well as T cells, and dramatically increased Gzmb expression in M1-like macrophages with combination therapy. Combination therapy modulated TGFβ-mediated cellular crosstalk and extracellular matrix (ECM) remodeling. CONCLUSIONS: Our findings suggest that inhibition of adenosine activity by blocking the A2B receptor reduces TGFβ signaling and enhances the efficacy of ICI therapy in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentReceptor, Adenosine A2BProgrammed Cell Death 1 ReceptorAdenosine A2 Receptor AntagonistsCarcinoma, Lewis LungImmune Checkpoint InhibitorsLung NeoplasmsAnimalsMiceCell Line, TumorHumansMice, Inbred C57BL

Stichwörter der Autor:innen

AdenosineImmunotherapySingle cell sequencingTumor microenvironment

Substanzen

Receptor, Adenosine A2BProgrammed Cell Death 1 ReceptorAdenosine A2 Receptor AntagonistsImmune Checkpoint InhibitorsPdcd1 protein, mouse

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.
  • Pelotonia Institute for Immuno-Oncology, OSUCCC-James, The Ohio State University, Columbus, OH, USA.
  • Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. David.Carbone@osumc.edu.
  • Pelotonia Institute for Immuno-Oncology, OSUCCC-James, The Ohio State University, Columbus, OH, USA. David.Carbone@osumc.edu.

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Guan, S., Wang, C., Amann, J. M., Cho, J. H., Ma, Q., & Carbone, D. P. (2026). Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04330-1

Vancouver

Guan S, Wang C, Amann JM, Cho JH, Ma Q, Carbone DP. Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04330-1

BibTeX
@article{Guan2026,
  author = {Guan, Shuxiao and Wang, Cankun and Amann, Joseph M and Cho, Ju Hwan and Ma, Qin and Carbone, David P},
  title = {Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04330-1}
}
Kostenlos starten →